JP2004525962A5 - - Google Patents

Download PDF

Info

Publication number
JP2004525962A5
JP2004525962A5 JP2002580951A JP2002580951A JP2004525962A5 JP 2004525962 A5 JP2004525962 A5 JP 2004525962A5 JP 2002580951 A JP2002580951 A JP 2002580951A JP 2002580951 A JP2002580951 A JP 2002580951A JP 2004525962 A5 JP2004525962 A5 JP 2004525962A5
Authority
JP
Japan
Prior art keywords
acid
bile
radical
general formula
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002580951A
Other languages
English (en)
Japanese (ja)
Other versions
JP4324706B2 (ja
JP2004525962A (ja
Filing date
Publication date
Priority claimed from IL142650A external-priority patent/IL142650A/en
Application filed filed Critical
Publication of JP2004525962A publication Critical patent/JP2004525962A/ja
Publication of JP2004525962A5 publication Critical patent/JP2004525962A5/ja
Application granted granted Critical
Publication of JP4324706B2 publication Critical patent/JP4324706B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002580951A 2001-04-17 2002-04-15 胆汁酸または胆汁酸塩脂肪酸結合体の使用 Expired - Lifetime JP4324706B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL142650A IL142650A (en) 1998-04-08 2001-04-17 Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
PCT/IL2002/000303 WO2002083147A1 (en) 2001-04-17 2002-04-15 Use of bile acid or bile salt fatty acid conjugates

Publications (3)

Publication Number Publication Date
JP2004525962A JP2004525962A (ja) 2004-08-26
JP2004525962A5 true JP2004525962A5 (https=) 2005-12-22
JP4324706B2 JP4324706B2 (ja) 2009-09-02

Family

ID=11075322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002580951A Expired - Lifetime JP4324706B2 (ja) 2001-04-17 2002-04-15 胆汁酸または胆汁酸塩脂肪酸結合体の使用

Country Status (24)

Country Link
US (2) US7501403B2 (https=)
EP (2) EP1379254B1 (https=)
JP (1) JP4324706B2 (https=)
KR (1) KR100883080B1 (https=)
CN (1) CN1259918C (https=)
AT (2) ATE432705T1 (https=)
AU (2) AU2002307771B2 (https=)
BR (1) BR0208924A (https=)
CA (2) CA2703688C (https=)
CY (1) CY1106853T1 (https=)
CZ (2) CZ309042B6 (https=)
DE (2) DE60232559D1 (https=)
DK (2) DK1790346T3 (https=)
EA (1) EA007565B1 (https=)
ES (2) ES2289137T3 (https=)
HU (1) HU230548B1 (https=)
IL (1) IL142650A (https=)
MX (1) MXPA03009553A (https=)
NO (2) NO333910B1 (https=)
NZ (1) NZ528868A (https=)
PL (2) PL211438B1 (https=)
PT (2) PT1379254E (https=)
UA (1) UA78699C2 (https=)
WO (1) WO2002083147A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142650A (en) 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
US8975246B2 (en) * 2001-04-17 2015-03-10 Galmed Research And Development Ltd. Bile acid or bile salt fatty acid conjugates
SI2182954T1 (sl) * 2007-07-25 2019-04-30 Medizinische Universitat Graz Uporaba nor-žolčnih kislin pri zdravljenju arterioskleroze
RS56054B1 (sr) * 2009-01-12 2017-09-29 Biokier Inc Smeša i metod za lečenje dijabetesa
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US20120157419A1 (en) 2009-02-02 2012-06-21 Tuvia Gilat Methods and compositions for treating alzheimer's disease
US20120202890A1 (en) 2011-02-08 2012-08-09 Nian Wu Polymer-carbohydrate-lipid conjugates
BR112014027204A2 (pt) 2012-05-01 2017-06-27 Catabasis Pharmaceuticals Inc conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos
CN103571617A (zh) * 2012-07-26 2014-02-12 丰益(上海)生物技术研发中心有限公司 改进的动物油脂加工工艺
WO2014084421A1 (en) * 2012-11-29 2014-06-05 Mediplex Corp. Bile acid oligomer conjugate for novel vesicular transport and use thereof
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
SI3077047T1 (sl) * 2013-12-04 2019-09-30 Galmed Research & Development Ltd. Soli aramchola
JP2017519726A (ja) * 2014-06-01 2017-07-20 ガルメッド リサーチ アンド ディベロップメント リミテッド． リポジストロフィー治療用脂肪酸胆汁酸複合体
US10849911B2 (en) 2015-06-10 2020-12-01 Galmed Research And Development Ltd. Low dose compositions of Aramachol salts
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CN116687850A (zh) 2022-02-24 2023-09-05 甘莱制药有限公司 包含环状膦酸酯化合物的药物组合物及其制备方法与用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859437A (en) * 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels
US3856953A (en) * 1973-05-15 1974-12-24 Intellectual Property Dev Corp Method of treating fatty liver
IT1167479B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido chenodesossicolico
IT1167478B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido ursodesossicolico
JPS6164701A (ja) * 1984-09-06 1986-04-03 Meito Sangyo Kk カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5278320A (en) 1992-09-11 1994-01-11 Merck & Co., Inc. Cholesterol lowering compounds produced by directed biosynthesis
DE4432708A1 (de) * 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity
IL123998A (en) * 1998-04-08 2004-09-27 Galmed Int Ltd Conjugates of bile salts and pharmaceutical preparations containing them
IL142650A (en) * 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドｘ受容体活性化剤

Similar Documents

Publication Publication Date Title
JP2004525962A5 (https=)
CA2444266A1 (en) Use of bile acid or bile salt fatty acid conjugates
IL171331A (en) Use of a combination comprising safinamide and levodopa/pdi in the manufacture of a medicament for treating parkinson's disease and compositions and a kit comprising said combination for such a treatment
EP1614675A3 (en) Amino acids with affinity for the alpha-2-delta protein
WO2009028457A1 (ja) 非アルコール性脂肪肝炎治療薬
EP2554540A3 (en) 3-Cyclyl-2-(4-sulfamoyl-phenyl)-n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
MA27431A1 (fr) Derives de pyrimidinone utilises comme agents therapeutiques contre des processus inflammatoires ischemiques et de remodelage aigus et chroniques
EP2573079A3 (en) Benzimidazole quinolinones and uses thereof
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
ID26042A (id) Turunan-turunan asam lemak dari asam-asam empedu dan asam empedu
WO2005082863A3 (en) 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
Chircorian et al. Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au (I)
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
EP1612208A3 (en) N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation
EP2597083A3 (en) Selective hydroxamate based MMP inhibitors
WO2006130532A3 (en) Treatment of liver diseases in which iron plays a role in pathogenesis
NZ516290A (en) Substituted phenoxyacetic acids
IL192190A0 (en) Process for the preparation of pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.
WO2003000173A3 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
WO2004045552A3 (en) Compositions for treating and/or preventing diseases characterized by the presence of metal ions
WO2006005611A3 (en) Glucocorticoid 16alpha,17.alpha.-isoxazolidines as anti-inflammatory agents
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2005085240A3 (en) Process for the preparation of ziprasidone
WO2005103690A3 (en) Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)